Meeting
2018 Genitourinary Cancers Symposium
Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).
Authors
Daniel Khalaf
British Columbia Cancer Agency - Vancouver Centre, Vancouver, BC, Canada
Daniel Khalaf , Cameron Herberts , Gillian Vandekerkhove , Matti Annala , Kevin Beja , Bernhard J. Eigl , Christian K. Kollmannsberger , Lucia Nappi , Joanna Vergidis , Alexander William Wyatt , Kim N. Chi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 260)
DOI
10.1200/JCO.2018.36.6_suppl.260
Abstract #
260
Poster Bd #
M14
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
First Author: Leta Ko
Poster
2023 ASCO Annual Meeting
Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.
First Author: Anis Hamid
Poster
2021 Genitourinary Cancers Symposium
Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).
First Author: Fadi Taza
Poster
2019 ASCO Annual Meeting
AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.
First Author: Marcus W. Moses